Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that its scientists and collaborators will present pre-clinical and clinical data with patisiran (ALN-TTR02) and ALN-TTRsc – RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR) – at the XIVth International Symposium on Amyloidosis (ISA) being held April 27 – May 1, 2014 in Indianapolis, Indiana. Amongst other new data, the company presentations include results from a 283-patient natural history study of ATTR patients with familial amyloidotic polyneuropathy (FAP) that document the rate of disease progression.
Help employers find you! Check out all the jobs and post your resume.
